Wegovy Manufacturing Delays Highlight Challenges Of Managing Aging Facility Risks

While pharmaceutical manufacturing facilities can age well, the care and attention aging facilities require can arise at inopportune moments, as was the case for Novo’s Wegovy launch. Even so, Catalent aims to make quick work of air handler replacement to get the new weight-loss drug back into production, despite typically long lead times, consultant says.

Vial filling
a question of when to update filling lines • Source: Alamy

Efforts to remediate Catalent, Inc’s manufacturing site in Brussels, Belgium, to address US FDA inspectional observations and restore production of Novo Nordisk A/S’s just-launched Wegovy (semaglutide) reflect some of the challenges manufacturers face in keeping facilities fit as they age.

Catalent describes the Brussels plant as its flagship European syringe filling facility, with more than 70 years of biologics and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Compliance